...is using to deliver synthetic versions of the peptides. According to CEO and CSO Thomas Rademacher...
...of development. Sanofi has said the vaccine cost about €1.5 billion ($1.8 billion) to develop. Rademacher...
...nanoparticle candidates in post-infectious blood to select the ones that trigger the strongest immune responses. Rademacher...

...any unconjugated linkers on the surface that could cause an immune response," he said. Thomas Rademacher...

...invading pathogen by displaying bacterial cell surface proteins, such as toll-like receptor (TLR) ligands. Thomas Rademacher...
...of adjuvant and antigen because the latter approach results in the adjuvant diffusing away. Thus, Rademacher...
...are associated with toxicity due to excessive release of chemokines and cytokines, he said. Similarly, Rademacher...

...full ownership of Innopeg, a 2002 joint venture formed with Rodaris. Also, SPA acquired from Rodaris...
...diseases, diabetes, and obesity to diagnose preeclampsia. SPA intends to outlicense some of the molecules. Rodaris Pharmaceuticals Ltd....

...assigned patent rights covering IPGs and hormone and growth factor mimetics to the joint venture. Rademacher...

...SR Pharma (LSE:SPA) and the Rademacher Group (Oxford, U.K.) set up a 50:50 joint venture to...

...Hoeft Rademacher Ltd., London, U.K. Business: Metabolic Hired: Sijmen de Vries as CEO, formerly director, market...

...Partners EuroGene £0.25M Anglo-Finnish start-up in cardiovascular diseases attracts seed financing from Merlin Ventures Hoeft Rademacher...

...practicing this approach, this year taking the lead in a couple of deals - Hoeft Rademacher...